FULC

Fulcrum Therapeutics, Inc. Common Stock
Data: 2026-04-28
$7.44
Price
-3.63%
Change
$15.74
52W High
$3.45
52W Low

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Quick Stats
Apr 28, 2026

57.3

AI Score

HOLD

0.62

Volume Ratio

Apr 27, 2026

Next Earnings

13

+ve Days (30d)

16

-ve Days (30d)

FULC Stock Summary

Last updated Apr 28, 2026

FULC is currently trading at $7.44, positioned below its 200-day moving average of $8.86, suggesting bearish momentum. The stock has a 52-week range of $3.45 to $15.7399.

Technical Analysis: The 50-day moving average stands at $8.05, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 44.316, suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.085, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates FULC at 57.3/100 with a HOLD recommendation.

FULC (Fulcrum Therapeutics, Inc. Common Stock) Indicators

Last updated Apr 28, 2026

Indicator Value
RSI(14) 44.316
CMF (20) 0.085
ROC (10) -5.823
ADX (14) 12.601
Indicator Value
MACD (12,26,9) -0.048
AROONOSC (14) -35.714
WILLAMS %R (14) -68.382
MFI (14) 47.725
FULC Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators

Select indicators above to analyze technical patterns

Indicators will appear below the price chart with perfectly aligned dates

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

FULC Price vs Max Options Open Interest
FULC Max Change In Options Open Interest

FULC Options - Sort by Max open Interest (near term)

29th April 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

FULC Daily Out of Money Options - Sort by Max open Interest (near term)

29th April 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

FULC Daily In the Money Options - Sort by Max open Interest (near term)

29th April 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

FULC Most Active Options by Volume(near term)

29th April 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI
Ask PC Delta Vega Volatility % change Track

Fulcrum Therapeutics, Inc. Common Stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.

FULC Moving Averages Analysis

FULC (Fulcrum Therapeutics, Inc. Common Stock) Simple Moving Averages

Moving Averages are last updated Apr 28, 2026

Days MA
10 7.88
20 7.83
30 7.52
50 8.05
100 9.55
200 8.86

FULC Fundamental Analysis

P/E (Forward) 0
P/E (Trailing) --
Market Cap ($) 514.4 million
Earnings/Share ($) -1.15
Net Proft Margin (%) 0
Dividend/Share ($) --
EPS Estimate Current Year ($) -1.2021
EPS Estimate Next Year ($) -1.5152
WallStreet Target Price ($) 19
Most Recent Quarter